On Apr 11, 2017, A New Jersey federal judge entered
a final judgment and injunction barring Actavis Inc.,
Roxane Laboratories Inc. and Alkem Laboratories Ltd. from releasing generic
versions of Depomed Inc.’s opioid painkiller Nucynta (tapentadol) until
related patents expire.
This final judgment is related to the opinion issued by New
Jersey district court on Jan 13, 2017. In this opinion District court found that
Alkem infringed all the three asserted patents (US patent nos. RE39593 expiring
on Aug 5, 2022; 7994364 expiring on Jun 27, 2025 & 8536130 expiring on Sep
22, 2028) whereas Actavis & Roxane infringed 2 patents (US’593 & US’364).
Also defendants have failed to prove by clear & convincing standard that
these 3 patents are invalid.
Buy Tapentadol online a good pain reliever pill to treat moderate to severe pain effectively. This medicine starts functioning instantly after the intake.
ReplyDelete